Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function
Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder characterized by prolonged inflammation of the gastrointestinal tract. IBD can result from gut barrier dysfunction, altered gut microbiota, and abnormal intestinal immunity induced by environmental factors in genetically suscepti...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.870817/full |
| _version_ | 1811255320229445632 |
|---|---|
| author | Mijeong Son I Seul Park Soochan Kim Hyun Woo Ma Ji Hyung Kim Tae Il Kim Won Ho Kim Jaeyong Han Seung Won Kim Seung Won Kim Jae Hee Cheon Jae Hee Cheon |
| author_facet | Mijeong Son I Seul Park Soochan Kim Hyun Woo Ma Ji Hyung Kim Tae Il Kim Won Ho Kim Jaeyong Han Seung Won Kim Seung Won Kim Jae Hee Cheon Jae Hee Cheon |
| author_sort | Mijeong Son |
| collection | DOAJ |
| description | Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder characterized by prolonged inflammation of the gastrointestinal tract. IBD can result from gut barrier dysfunction, altered gut microbiota, and abnormal intestinal immunity induced by environmental factors in genetically susceptible individuals. Proton pump inhibitors (PPIs) such as rabeprazole are frequently employed for gastric acid inhibition. However, long-term PPI administration can alter the intestinal microbiome composition, possibly worsening IBD severity. The present study revealed that tegoprazan, a potassium-competitive acid blocker, significantly improved colitis in mice and enhanced the intestinal epithelial barrier function. Tegoprazan alleviated gut microbiota dysbiosis and enhanced the growth of Bacteroides vulgatus. In turn, B. vulgatus alleviated intestinal inflammation by inhibiting epithelial adhesion of pathogenic bacteria. Unlike rabeprazole, tegoprazan did not induce gut dysbiosis. Our findings provide novel insights into the potential role of tegoprazan as an intestinal protectant for IBD and as a therapeutic agent for gastric acid-related diseases. |
| first_indexed | 2024-04-12T17:22:03Z |
| format | Article |
| id | doaj.art-de450bbca78648bcac25a30f09f4f2cd |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-12T17:22:03Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-de450bbca78648bcac25a30f09f4f2cd2022-12-22T03:23:26ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-05-011310.3389/fimmu.2022.870817870817Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier FunctionMijeong Son0I Seul Park1Soochan Kim2Hyun Woo Ma3Ji Hyung Kim4Tae Il Kim5Won Ho Kim6Jaeyong Han7Seung Won Kim8Seung Won Kim9Jae Hee Cheon10Jae Hee Cheon11Department of Internal Medicine and Institute of Gastroenterology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South KoreaDepartment of Internal Medicine and Institute of Gastroenterology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South KoreaDepartment of Internal Medicine and Institute of Gastroenterology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South KoreaDepartment of Internal Medicine and Institute of Gastroenterology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South KoreaDepartment of Internal Medicine and Institute of Gastroenterology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South KoreaDepartment of Internal Medicine and Institute of Gastroenterology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South KoreaDepartment of Internal Medicine and Institute of Gastroenterology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South KoreaDepartment of Internal Medicine, Cha Ilsan Medical Center, CHA University, Goyang, South KoreaDepartment of Internal Medicine and Institute of Gastroenterology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South KoreaSeverance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South KoreaDepartment of Internal Medicine and Institute of Gastroenterology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South KoreaSeverance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South KoreaInflammatory bowel disease (IBD) is a chronic immune-mediated disorder characterized by prolonged inflammation of the gastrointestinal tract. IBD can result from gut barrier dysfunction, altered gut microbiota, and abnormal intestinal immunity induced by environmental factors in genetically susceptible individuals. Proton pump inhibitors (PPIs) such as rabeprazole are frequently employed for gastric acid inhibition. However, long-term PPI administration can alter the intestinal microbiome composition, possibly worsening IBD severity. The present study revealed that tegoprazan, a potassium-competitive acid blocker, significantly improved colitis in mice and enhanced the intestinal epithelial barrier function. Tegoprazan alleviated gut microbiota dysbiosis and enhanced the growth of Bacteroides vulgatus. In turn, B. vulgatus alleviated intestinal inflammation by inhibiting epithelial adhesion of pathogenic bacteria. Unlike rabeprazole, tegoprazan did not induce gut dysbiosis. Our findings provide novel insights into the potential role of tegoprazan as an intestinal protectant for IBD and as a therapeutic agent for gastric acid-related diseases.https://www.frontiersin.org/articles/10.3389/fimmu.2022.870817/fullBacteroides vulgatusinflammatory bowel diseasepotassium-competitive acid blockerproton pump inhibitorgut barrier function |
| spellingShingle | Mijeong Son I Seul Park Soochan Kim Hyun Woo Ma Ji Hyung Kim Tae Il Kim Won Ho Kim Jaeyong Han Seung Won Kim Seung Won Kim Jae Hee Cheon Jae Hee Cheon Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function Frontiers in Immunology Bacteroides vulgatus inflammatory bowel disease potassium-competitive acid blocker proton pump inhibitor gut barrier function |
| title | Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function |
| title_full | Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function |
| title_fullStr | Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function |
| title_full_unstemmed | Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function |
| title_short | Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function |
| title_sort | novel potassium competitive acid blocker tegoprazan protects against colitis by improving gut barrier function |
| topic | Bacteroides vulgatus inflammatory bowel disease potassium-competitive acid blocker proton pump inhibitor gut barrier function |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.870817/full |
| work_keys_str_mv | AT mijeongson novelpotassiumcompetitiveacidblockertegoprazanprotectsagainstcolitisbyimprovinggutbarrierfunction AT iseulpark novelpotassiumcompetitiveacidblockertegoprazanprotectsagainstcolitisbyimprovinggutbarrierfunction AT soochankim novelpotassiumcompetitiveacidblockertegoprazanprotectsagainstcolitisbyimprovinggutbarrierfunction AT hyunwooma novelpotassiumcompetitiveacidblockertegoprazanprotectsagainstcolitisbyimprovinggutbarrierfunction AT jihyungkim novelpotassiumcompetitiveacidblockertegoprazanprotectsagainstcolitisbyimprovinggutbarrierfunction AT taeilkim novelpotassiumcompetitiveacidblockertegoprazanprotectsagainstcolitisbyimprovinggutbarrierfunction AT wonhokim novelpotassiumcompetitiveacidblockertegoprazanprotectsagainstcolitisbyimprovinggutbarrierfunction AT jaeyonghan novelpotassiumcompetitiveacidblockertegoprazanprotectsagainstcolitisbyimprovinggutbarrierfunction AT seungwonkim novelpotassiumcompetitiveacidblockertegoprazanprotectsagainstcolitisbyimprovinggutbarrierfunction AT seungwonkim novelpotassiumcompetitiveacidblockertegoprazanprotectsagainstcolitisbyimprovinggutbarrierfunction AT jaeheecheon novelpotassiumcompetitiveacidblockertegoprazanprotectsagainstcolitisbyimprovinggutbarrierfunction AT jaeheecheon novelpotassiumcompetitiveacidblockertegoprazanprotectsagainstcolitisbyimprovinggutbarrierfunction |